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558Objective: The aim of the present study was to compare the hydrodynamics of 4 different mechanical prostheses
fitting the atrioventricular annulus in children.
Methods:We tested different inverted aortic prostheses with a prosthesis–annulus relationship in the mi-
tral chamber of the Sheffield pulse duplicator (Department of Medical Physics and Clinical Engineering,
Royal Hallamshire Hospital, Sheffield, UK), analyzed by comparing the prosthetic housing diameter and
the predicted annulus diameter based on body surface area (0.8 and 1 m2 corresponding to an annulus
diameter of 18.8–20.2 mm). The On-X 19 (On-X Life Technologies, Inc, Austin, Tex), SJM Regent 19
(St Jude Medical Inc, St Paul, Minn), Sorin Overline 18 (Sorin Biomedica, Saluggia, Italy), and Med-
tronic Advantage Supra 19 (Medtronic Inc, Minneapolis, Minn) valves with a housing diameter of 19
to 20 mm were hydrodynamically compared. The tests were carried out at increasing pulse rate of 72,
80, 100, and 120 beats/min for a stroke volume of 20 and 30 mL. Therefore, cardiac output ranged
from 1.44 to 3.6 L/min.
Results:Regardless of the pulse rate and stroke volume, the Medtronic Advantage Supra valve showed the high-
est mean diastolic pressure difference at each cardiac output (P<.05). The mean gradients were significantly
lower for the Sorin Overline valve regardless of the cardiac output, stroke volume, and pulse rate (P<.05).
The effective orifice areas observed followed exactly the same behavior: the lowest for theMedtronic Advantage
Supra valve and the highest for the Sorin Overline valve. The Sorin Overline valve showed the highest closure
volumes (P<.05), and the On-X prosthesis showed the highest leakage volumes (P<.05). The Sorin Overline
valve had the highest total regurgitant volume (P<.05), and the Medtronic Advantage Supra valve had the low-
est total regurgitant volume (P<.05). The On-X valve showed the highest total energy loss regardless of the
pulse rate at 20 mL of stroke volume, which was comparable to the SJM Regent and Sorin Overline valves at
increased stroke volume. The Medtronic Advantage Supra valve showed the lowest total energy loss regardless
of cardiac outputs (P<.05).
Conclusions: This hydrodynamic evaluation model allowed us to compare the efficiency of currently avail-
able valve prostheses suitable for atrioventricular replacement in children. Among these prostheses, the
Sorin Overline valve showed the best diastolic performance. On the other hand, for total energy loss, the
Medtronic Advantage Supra valve demonstrated excellent performance. (J Thorac Cardiovasc Surg
2012;143:558-68)Repair of the mitral valve in children is the preferred surgi-
cal option, but dysplastic valves and complicated patholo-
gies of the mitral apparatus may present technical
difficulties, and valve replacement may be necessary.
Evaluation of the hydrodynamics of prosthetic valves is
a useful indicator of expected clinical performance, but
has the hypothetic differential hydraulic behavior betweene Cardiovascular Institute, University of Padova, Italy.
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The Journal of Thoracic and Cardiovascular Surgdifferent prosthetic mitral heart valves been sufficiently
and comprehensively revealed?
All valve substitutes are responsible for some residual
stenosis because of the design, size, material, and im-
plantation technique used. This can be minimized by an
accurate surgical strategy and preoperative prosthesis se-
lection.1-5 To answer our question in this report, we
analyzed the hydrodynamic performance of 4 bileaflet
mechanical prostheses: On-X 19 (On-X Life Technolo-
gies, Inc, Austin, Tex), SJM Regent 19 (St Jude Medical
Inc, St Paul, Minn), Sorin Overline 18 (Sorin Biomedica,
Saluggia, Italy), and Medtronic Advantage Supra 19
(Medtronic Inc, Minneapolis, Minn). All prostheses, re-
gardless of the manufacturer’s nominal size, were fitted
onto a 21-mm diameter valve holder of the Sheffield
pulse duplicator (SPD; Department of Medical Physicsery c March 2012
Abbreviations and Acronyms
CO ¼ cardiac output
EOA ¼ effective orifice area
LA ¼ left atrium
MVR ¼ mitral valve replacement
PR ¼ pulse rate
SD ¼ standard deviation
SPD ¼ Sheffield pulse duplicator
SV ¼ stroke volume
TEL ¼ total energy loss
TRV ¼ total regurgitant volume
VCV ¼ valve closing volume
VLV ¼ valve leakage volume
Bottio et al Congenital Heart Disease
C
H
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Sheffield, UK).MATERIALS AND METHODS
The SPD is a system designed to perform pulsatile hydrodynamic
testing of prosthetic heart valves by means of continuous measurement
of flow and transvalvular pressure gradients (Figure 1). The system has
been described in detail.6-8 We tested different inverted aortic prostheses
in the mitral chamber of the SPD with a prosthesis–annulus relationship
analyzed by comparing the prosthetic housing diameter and the predicted
annulus diameter based on the body surface area of the subjects. We
considered a body surface area of 0.8 to 1 m2 corresponding to an
annulus diameter of 18.8 to 20.2 mm in children. Three production
quality samples of each model were tested. Each valve was tested 10
times at each different cardiac output (CO). This resulted in 40 tests
for each valve and 120 tests for each valve model. The mean and
standard deviation (SD) of each measurement parameter for each test
condition was calculated from the 10 repeated tests on each valve. The
sizes of the tested valves fitting an annulus diameter from 18.8 to 20.2
mm were as follows: On-X, 19; SJM Regent, 19; Sorin Overline, 18;
and Medtronic Advantage Supra, 19. We considered the housing diame-
ter as external diameter, and a larger label size of each prosthesis could
not be accommodated in a 21-mm SPD holder. The prostheses wereFIGURE 1. The SPD. (Reprinted with permission
The Journal of Thoracic and Cahydrodynamically compared. Thus, the valves were inserted into the
pulse duplicator holder composed of 2 O-rings, and the prosthesis was
secured between these rings. A supplied rubber washer was used to fill
and seal the gap between the 2 parts of the mounting ring. Therefore, par-
avalvular leakage was not allowed in any test. Simultaneous pressure
measurements were recorded by using electromagnetic flowmeters and
pressure transducers located upstream and downstream of the mitral
valve. Each valve was tested at a different stroke volume (SV) and pulse
rate (PR) to assess the change in the prostheses’ hydrodynamics during
hypothetic somatic growth. The tests were carried out at increasing PR
of 72, 80, 100, and 120 beats/min for an SVof 20 and 30 mL. CO varied
between 1.44 and 3.6 L/min (representative of 0.8–1.2 m2 body surface
area and in the range of COs required by the Food and Drug Administra-
tion for in vitro tests). The aortic pressures were kept constant at 120/80
mm Hg. The system was filled with saline solution (0.9%), as recom-
mended by the manufacturer, to optimize measurements.9 Forward
flow pressure decrease, closing volume, leakage volume, total regurgi-
tant volume (TRV), and effective orifice area (EOA ¼ [root mean square
diastolic flow rate {milliliters/second}/51.6 * square root mean diastolic
pressure difference {millimeters mercury}/1.0085]) were calculated as
previously published by Walker and colleagues10 and according to the
SPD Manual (Figure 2). All data were expressed as means  SD.
The chi-square test was used for statistical comparison. The following
parameters were determined for each cardiac cycle: mean gradient (mil-
limeters mercury), EOA (square centimeters), performance index (EOA,
square centimeters/external diameter, centimeters), TRV (milliliters),
valve closing volume (VCV, milliliters), valve leakage volume (VLV,
milliliters), and total energy loss (TEL, calculated by integrating the
flow times the transvalvular pressure over relevant flow interval). A con-
version factor of 0.1333 is applied to convert the energy from millime-
ters mercury to millijoule). All 7 mitral timing points considered by the
SPD software are shown in Figure 2.RESULTS
Measurements for All Valve Models (Figure 3)
Table 1 shows the measurements for all valve models by
nominal size. The value is a mean measurement made with
a highly professional ruler. Two different independent in-
vestigators measured all the prostheses. Measurements are
the expression of a mean value of 3 different valves for
each model, including the maximum and minimum values
obtained for each valve.from the SPD Instructions Manual, page 5.9)
rdiovascular Surgery c Volume 143, Number 3 559
FIGURE 2. Mitral timing points. (Reprinted with permission from the SPD Instructions Manual, page 35.9)
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ameter was observed for the Sorin Overline valve, followed
by the SJM Regent and On-X valve. However, when com-
pared with the label size, the actual internal orifice diameter
was inferior by 2.2 mm for the Medtronic Advantage Supra,
by 1.6 mm for the On-X valve, and by 1.2 mm for the SJM
Regent valve. Only the Sorin Overline valve had an internal
diameter equal to the label size.
External orifice diameter. The largest external diameter
was observed for the On-X valve (20.1 mm) followed by
the Sorin Overline (19.2 mm), SJM Regent (19 mm), and
Medtronic Advantage Supra (18.5 mm) valves.
Height. The On-X (10.8 mm) and SJM Regent (9.07 mm)
are the tallest prostheses. The Sorin Overline (6.6 mm) and
Medtronic Advantage Supra (6 mm) are the shortest
prostheses.TABLE 1. Measurements made for all valve models by nominal size
Model Label size
On-X (On-X Life Technologies, Inc, Austin, Tex) 19
SJM Regent (St Jude Medical Inc, St Paul, Minn) 19
Sorin Overline (Sorin Biomedica, Saluggia, Italy) 18
Medtronic ADV Supra (Medtronic Inc, Minneapolis, Minn) 19
560 The Journal of Thoracic and Cardiovascular SurgIn Vitro Performances
Stroke volume 20. The obtained mean values and SDs are
expressed according to the 4 COs adopted. The results are
shown in Tables 2 to 5 and Figures 4 and 5.
Mean gradients. The Medtronic Advantage Supra had the
highest mean gradients compared with the other tested
valves (P< .05), showing a rapid increase from 0.41 to
1.03 mm Hg when the PR increased from 80 to 120 beats/
min. The other prostheses showed significantly lower
mean gradients (P<.05). The On-X valve had mean gradi-
ent values comparable to the Medtronic Advantage Supra
valve only at 72 and 80 beats/min (P>.05). The Sorin Over-
line valve showed the lowest mean gradients when com-
pared with the other tested valves (P<.05).
Effective orifice area. The Sorin Overline valve showed
the highest EOA regardless of CO (P< .05). The EOAExternal diameter (mm) Internal diameter (mm) Height (mm)
20.1 17.4 10.8
19 17.8 9.07
19.2 18 6.6
18.5 16.8 6
ery c March 2012
TABLE 2. Medtronic Advantage Supra 19: Obtained mean values and standard deviations expressed according to each cardiac output adopted
Model
Cardiac output
(L/min)
Pulse rate
(beats/min)
Stroke
volume (mL)
Mean diastolic pressure
difference (mm Hg)
Total regurgitant
volume (mL)
Valve closing
volume (mL)
Medtronic Advantage Supra 19 1.44 72 20 0.41  0.02 2.02  0.13 1.32  0.24
2.16 72 30 0.94  0.03 1.52  0.12 1.07  0.17
1.60 80 20 0.42  0.02 2.45  0.16 1.50  0.18
2.40 80 30 1.05  0.03 2.1  0.17 1.18  0.20
2.00 100 20 0.69  0.02 2.25  0.19 1.46  0.15
3.00 100 30 1.69  0.03 1.83  0.15 1.09  0.15
2.40 120 20 1.03  0.02 1.92  0.15 1.31  0.18
3.60 120 30 2.47  0.05 1.51  0.14 0.96  0.14
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Dobserved with the Medtronic Advantage Supra valve at 72
and 80 beats/min was comparable to those observed with
the On-X valve (P>.05) but significantly diverged at in-
creasing PRs.
Total regurgitant volume. The Sorin Overline and On-X
valves showed the highest TRV for lower COs, becoming
significantly higher when PRs increased from 100 to 120
beats/min (P < .05). The Medtronic Advantage Supra
valve showed the lowest TRV, which was smaller for
each CO when compared with those obtained with the
other tested valves (P < .05). The SJM Regent valve
showed intermediate TRVs that were comparable to the
values obtained with the On-X valve at PRs of 100 and
120 beats/min (P>.05).
Valve closing volume. The Sorin Overline valve showed
the highest VCV at each CO in comparison with the
other tested valves (P< .05). The performances of the
other 3 valves were statistically different. The Medtronic
Advantage Supra had low values of VCV at each CO and
a rather stable hemodynamic behavior for increased
COs.
Valve leakage volume. The On-X valve showed the high-
est VLV at each CO, showing decreasing values for PRsTABLE 3. St Jude Reagent 19: Obtained mean values and standard devia
Model
Cardiac output
(L/min)
Pulse rate
(beats/min)
Stroke
volume (mL)
St Jude Reagent 19 1.44 72 20
2.16 72 30
1.60 80 20
2.40 80 30
2.00 100 20
3.00 100 30
2.40 120 20
3.60 120 30
The Journal of Thoracic and Caranging from 100 to 120 beats/min (P< .05). Both the
SJMRegent and Sorin Overline valves showed intermediate
values, being comparable at 72 and 80 beats/min PRs (P>
.05) and becoming significantly different at increasing PRs
(P<.05). The Medtronic Advantage Supra valve showed
the lowest VLV, which was significantly lower at each
CO, when compared with that obtained with the other
valves (P<.05).
Total energy loss. The On-X valve showed the highest
TEL at 72, 80, and 100 beats/min of PR (P<.05), showing
decreasing values at the highest PR (P> .05). The Sorin
Overline valve showed the highest TEL at 120 beats/min
of PR (P< .05). The Medtronic Advantage Supra valve
showed the lowest TEL, which was significantly lower at
each CO, when compared with that obtained with the other
valves (P<.05).
Stroke Volume 30
The obtained mean values and SDs are expressed accord-
ing to the 4 COs adopted, and the results are shown in Tables
2 to 5 and Figures 4 and 5.
Mean gradients. The Medtronic Advantage Supra showed
the highest mean gradients in comparison with other testedtions expressed according to each cardiac output adopted
Mean diastolic pressure
difference (mm Hg)
Total regurgitant
volume (mL)
Valve closing
volume (mL)
0.14  0.01 3.00  0.12 1.80  0.18
0.52  0.02 3.98  0.11 2.25  0.29
0.27  0.01 3.49  0.18 1.90  0.21
0.60  0.02 4.15  0.15 2.26  0.19
0.43  0.02 3.57  0.14 2.13  0.23
0.97  0.02 3.42  0.14 1.95  0.21
0.65  0.01 3.19  0.13 1.95  0.20
1.39  0.02 3.37  0.18 2.01  0.21
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TABLE 2. Continued
Total energy loss
Valve leakage
volume (mL) EOA (cm2)
Performance
index (cm2/cm2) (mJ) (%)
Forward flow
energy loss (mJ)
Closing energy
loss (J)
Leakage energy
loss (mJ)
0.70  0.18 1.31  0.18 0.47 16.78 7.28 1.12 7.23 8.43
0.45  0.15 1.31  0.17 0.47 18.34 4.96 4.99 7.48 5.88
0.95  0.11 1.33  0.14 0.48 22.03 9.85 1.08 9.18 11.8
0.92  0.14 1.31  0.10 0.47 26.56 7.08 5.55 9.04 11.9
0.79  0.12 1.32  0.15 0.48 22.45 9.39 1.67 11.1 9.68
0.74  0.12 1.30  0.16 0.47 28.74 6.98 8.04 10.9 9.85
0.61  0.10 1.30  0.16 0.47 22.09 9.01 2.18 12.3 7.58
0.55  0.13 1.28  0.13 0.46 29.83 6.83 11.0 11.3 7.52
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mm Hg when the PR increased from 80 to 120 beats/min,
reflecting the same previous behavior. The other prostheses
showed significantly lower mean gradients (P<.05). The
Sorin Overline valve showed the lowest mean gradients
when compared with the other tested valves (P<.05).
Effective orifice area. The Sorin Overline showed the
highest EOA regardless of CO (P<.05). The SJM Regent,
Medtronic Advantage Supra, and On-X valves showed sta-
ble EOAs at increasing COs. The EOA observed with the
Medtronic Advantage Supra remained the lowest of the
group (P<.05).
Total regurgitant volume. As observed in the 20 mL SV
test conditions, the Sorin Overline valve showed the highest
TRV for each CO. Furthermore, the SJM Regent valve
showed slightly lower values, becoming comparable to
those observed with the Sorin Overline valve at maximal
CO (P> .05). The Medtronic Advantage Supra showed
the lowest TRV, which was smaller for each CO when com-
pared with those obtained with the other tested valves
(P<.05).
Valve closing volume. The Sorin Overline valve showed
the highest VCV at each CO in comparison with the otherTotal energy l
Valve leakage
volume (mL) EOA (cm2)
Performance
index (cm2/cm2) (mJ)
1.20  0.11 2.15  0.19 0.76 25.35
1.73  0.16 1.73  0.16 0.61 39.70
1.59  0.10 1.70  0.18 0.60 31.04
1.89  0.17 1.72  0.13 0.60 43.47
1.44  0.10 1.72  0.12 0.60 33.78
1.47  0.15 1.62  0.15 0.57 40.86
1.24  0.09 1.60  0.18 0.56 32.93
1.36  0.17 1.71  0.19 0.60 45.75
TABLE 3. Continued
562 The Journal of Thoracic and Cardiovascular Surgtested valves (P<.05). As observed in the previous test con-
ditions, the performances of the other 3 valves were statis-
tically different. The Medtronic Advantage Supra showed
the lowest values of VCV at 72 and 120 beats/min of PRs
(P< .05) and values comparable to those observed with
the On-X valve at intermediate COs (P>.05).
Valve leakage volume. The On-X Valve showed the high-
est VLV at each CO, with decreasing values at increasing
PR (P< .05). Both the SJM Regent and Sorin Overline
valves showed intermediate values, being comparable
only at 72 beats/min PR (P>.05) and significantly lower
for the Sorin Overline at increasing PR (P<.05). The Med-
tronic Advantage Supra valve showed the lowest VLV,
which was significantly lower at each CO, when compared
with that obtained with the other valves (P< .05), as ob-
served in the previous test conditions.
Total energy loss. The On-X Valve showed the highest
TEL at 72, 80, and 100 beats/min of PR, showing decreas-
ing values at increasing PRs (P<.05). The Sorin Overline
valve showed the highest TEL at the maximal CO
(P<.05), being comparable to that observed with the On-
X valve at 100 beats/min of PR. The Medtronic Advantage
Supra valve showed the lowest TEL, which wasoss
(%)
Forward flow
energy loss (mJ)
Closing energy
loss (J)
Leakage energy
loss (mJ)
11.1 0.33 10.4 14.7
10.9 2.59 15.6 21.3
13.9 0.55 11.8 18.7
11.8 2.69 16.8 24.0
14.7 0.75 15.8 17.2
10.4 4.15 17.8 18.9
13.7 1.10 17.1 14.7
10.8 4.89 22.8 18.0
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TABLE 4. On-X 19: Obtained mean values and standard deviations expressed according to each cardiac output adopted
Model
Cardiac output
(L/min)
Pulse rate
(beats/min)
Stroke
volume (mL)
Mean diastolic pressure
difference (mm Hg)
Total regurgitant
volume (mL)
Valve closing
volume (mL)
On-X 19 1.44 72 20 0.38  0.02 4.44  0.14 2.21  0.28
2.16 72 30 0.79  0.03 4.09  0.13 1.51  0.32
1.60 80 20 0.39  0.04 4.57  0.17 2.14  0.35
2.40 80 30 0.79  0.02 3.04  0.18 1.32  0.29
2.00 100 20 0.59  0.02 3.59  0.19 1.84  0.34
3.00 100 30 1.45  0.05 2.95  0.12 1.19  0.16
2.40 120 20 0.88  0.04 3.06  0.11 1.75  0.31
3.60 120 30 1.96  0.07 2.61  0.10 1.17  0.25
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obtained with the other valves (P<.05).
DISCUSSION
The evaluation of the hydrodynamics of prosthetic valves
is a useful indicator of expected clinical performance. The
aim of our study was to analyze the hydrodynamic perfor-
mance of mechanical prostheses suitable for mitral valve re-
placement (MVR) in children by comparing their in vitro
results regardless of label size.
MVR in infants and young children is an uncommon op-
eration that historically has carried a higher mortality and
worse long-term outcome than MVR in older children
(10–12 years).11,12 The clinical course of children aged
less than 5 years who undergo MVR is largely unknown,
and these patients often require a second or third MVR.
Raghuveer and colleagues13 recently reported that prosthe-
sis survival can be predicted on the basis of age at first
MVR and prosthesis size, dividing the pediatric patients
aged less than 5 years into 3 risk groups. The risk is high-
est in patients aged less than 2 years, receiving prostheses
less than 20 mm at first MVR. The medium-risk group is
identified as patients aged less than 2 years and prosthesis
size 20 mm or greater at first MVR or aged more thanTABLE 5. Sorin Overline 19: Obtained mean values and standard deviati
Model
Cardiac output
(L/min)
Pulse rate
(beats/min)
Stroke
volume (mL)
Overline 18 1.44 72 20
2.16 72 30
1.60 80 20
2.40 80 30
2.00 100 20
3.00 100 30
2.40 120 20
3.60 120 30
The Journal of Thoracic and Ca2 years and prosthesis size less than 20 mm at first
MVR. The low-risk group is identified as patients aged
more than 2 years and prosthesis size 20 mm or greater
at first MVR. The somatic growth is comparable regardless
of the need for a second MVR, and there is an increment in
prosthesis size at second MVR, suggesting continued an-
nular growth, despite being fixed to the sewing ring.13
However, the discrepancy between prosthesis size and
body weight is a predictor of outcome. Larger discrep-
ancies are associated with higher early mortality. In addi-
tion, all valve substitutes are responsible for some residual
stenosis because of design, size, material, and implantation
technique used. Obviously, this could be minimized by
an exacting surgical strategy and preoperative prosthesis
selection.1-8
In vivo echocardiographic analysis is useful because we
can calculate hemodynamic prosthetic performance by ob-
serving mean transvalvular gradient and continuity equa-
tion valve area (EOA).
Transvalvular gradient is dependent on flow and EOA,
and the EOA is clearly related to the internal diameter of
the prosthesis.5 Investigators have suggested the use of
a fixed value of in vivo measured EOA for compari-
son.5,14,15 However, the echocardiographic EOA hasons expressed according to each cardiac output adopted
Mean diastolic pressure
difference (mm Hg)
Total regurgitant
volume (mL)
Valve closing
volume (mL)
0.07  0.01 4.45  0.19 2.96  0.11
0.25  0.01 4.54  0.15 2.89  0.07
0.03  0.01 4.21  0.13 2.96  0.11
0.38  0.01 4.19  0.15 2.76  0.09
0.14  0.01 3.83  0.18 2.76  0.09
0.75  0.02 3.72  0.13 2.69  0.10
0.32  0.02 3.32  0.12 2.77  0.06
1.15  0.03 3.29  0.16 2.53  0.14
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Total energy loss
Valve leakage
volume (mL) EOA (cm2)
Performance
index (cm2/cm2) (mJ) (%)
Forward flow energy
loss (mJ)
Closing energy
loss (J)
Leakage energy
loss (mJ)
2.23  0.47 1.32  0.18 0.42 41.34 19.0 1.13 14.1 26.1
2.58  0.46 1.40  0.19 0.44 48.68 12.8 4.49 11.6 32.6
2.43  0.51 1.40  0.15 0.44 45.52 19.5 1.25 14.9 29.3
2.08  0.26 1.54  0.13 0.49 43.96 11.7 6.26 11.4 26.3
1.75  0.23 1.44  0.12 0.45 37.65 15.9 1.69 14.9 20.1
1.76  0.30 1.45  0.15 0.46 43.12 10.5 7.87 12.1 23.1
1.31  0.20 1.43  0.18 0.45 34.25 14.1 2.27 16.3 15.7
1.44  0.19 1.45  0.16 0.46 42.06 9.59 8.86 13.4 19.8
TABLE 4. Continued
Congenital Heart Disease Bottio et al
C
H
Dsome inherent variability mainly related to the techniques
used for its measurement and to a certain flow
dependency.16
Therefore, it is necessary to perform in vitro studies to
compare different mechanical prosthesis performances, as
already stated for the aortic position.8,17 This concept has
been put forward by other authors. Wagner and
associates18 are aware that the in vivo measurement of gra-
dients does not entirely represent the complex function of
a valve, suggesting the performance of in vitro studies to
complete what is already known from in vivo studies, and
thus permitting the addition of other new parameters, such
as TRV, VCV, VLV, and TEL, for the individual prostheses.
Ruzicka and colleagues19 recently integrated in vivo results
with those observed in vitro. However, the discussed in vitro
and in vivo results were all obtained in the aortic position
and were focused on aortic prosthesis–patient mismatch.
Nevertheless, the in vivo mitral prosthesis–patient mis-
match has been described by Li and colleagues5 and Pibarot
and Dumesnil.14
The hypothetic differential hydraulic behavior between
different prosthetic heart valves in the mitral position in
children has not been demonstrated. Therefore, wemaintain
that it is absolutely essential to compare the hydrodynamicTABLE 5. Continued
Total energy los
Valve leakage
volume (mL) EOA (cm2)
Performance
index (cm2/cm2) (mJ) (%
1.49  0.24 2.46  0.19 0.85 34.87 16
1.65  0.32 2.46  0.15 0.85 43.96 11
1.52  0.22 2.35  0.11 0.81 37.12 16
1.43  0.33 2.27  0.10 0.79 41.83 11
1.07  0.13 2.37  0.17 0.82 35.11 15
1.03  0.16 2.00  0.18 0.69 44.11 10
0.85  0.13 2.34  0.14 0.81 37.33 15
0.76  0.14 1.93  0.19 0.67 46.59 10
564 The Journal of Thoracic and Cardiovascular Surgperformances of different prostheses under defined and
identical test conditions to obtain a meaningful comparison
regardless of industry labeled size.
Our current study compared the hydrodynamic perfor-
mances of 4 different mechanical prostheses fitting the
atrioventricular annulus in children, regardless of label
size, choosing the valves by comparing the prosthetic hous-
ing diameter and the predicted annulus diameter, calculated
on the basis of body surface area. We observed that the label
size of the Sorin Overline and SJM Regent prostheses cor-
respond to the internal orifice diameter and external diame-
ter, respectively. On the other hand, the same industry
parameter does not correspond to any other measured di-
mensions for the Medtronic Advantage Supra and On-X
prostheses.
Therefore, the comparison of hydrodynamics of different
valve prostheses is difficult because of the lack of standard-
ization in labeling by manufacturers.20 With the aim of al-
lowing meaningful comparison that is relevant for clinical
application, we designed this innovative study to analyze
the hydrodynamics of these different bileaflet mechanical
prostheses.
The SPD was used for this in vitro study. This device is
not designed to give an accurate representation of the trues
)
Forward flow energy
loss (mJ)
Closing energy
loss (J)
Leakage energy
loss (mJ)
.2 0.15 17.2 17.8
.8 1.91 20.9 21.2
.7 0.06 18.9 18.3
.0 2.54 21.4 17.9
.1 0.26 22.1 12.8
.9 4.07 26.9 13.1
.5 0.53 26.7 10.1
.7 5.68 30.6 10.6
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FIGURE 3. The valves inserted into the SPD holder (21 mm), which is composed of 2 O-rings. Each prosthesis was secured between these rings fitting
perfectly, thus ensuring the lack of any perivalvular leakage, as shown: On-X (On-X Life Technologies, Inc, Austin, Tex); SJM Regent (St JudeMedical Inc,
St Paul, Minn); and Sorin Overline (Sorin Biomedica, Saluggia, Italy). The Medtronic Advantage (Medtronic Inc, Minneapolis, Minn) is shown in the SPD
during the tests.
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Danatomy, but it provides an extraordinary and unquestion-
able bench test for comparison of different prostheses ex-
posed to the same conditions.8 However, we have to keep
in mind that the transfer of the in vitro results to an
in vivo situation is limited because the in vivo hemody-
namic behavior of a valve may differ from in vitro idealized
assumptions.8 For example, one of the major limitations of
the current in vitro study is that the use of saline solution,
strongly suggested by the SPD manufacturer, may lead to
different results than those obtainable by using a fluid
with a viscosity similar to blood. Therefore, we maintain
that further studies comparing these in vitro results with
in vivo echocardiographic findings are of extreme impor-
tance. In addition, the discussed data are the results of an in-
dependent research study, in which all of the authors
disclaim any company relationship.
The mechanical aortic prosthesis may be inverted and
placed in the mitral position (into the native annulus or in
the supra-annular position), and used as a mitral valve sub-
stitute for pediatric patients undergoing MVR.
One option for maximizing the size of a mechanical pros-
thesis in small patients is to place the valve in a supra-
annular position, effectively within the left atrium (LA).
Despite the potential benefits of a larger prosthesis in small
children, supra-annular MVR has potential drawbacks, in-
cluding reduction of LAvolume and compliance, and aneu-
rysm formation in the ventricularized segment of the LAThe Journal of Thoracic and Cabetween the prosthesis and the annulus.14 Consequently, it
is mandatory to know the prostheses’ functional character-
istics according to different in vitro settings with the aim of
giving the surgeon a quick idea of the appropriate valve to
limit patient–prosthesis mismatch during somatic growth.
The current hydrodynamic evaluation model showed
that all the tested valves behave differently in every test
condition. In particular, the Sorin Overline valve possesses
the lowest transvalvular gradients and the highest EOA,
being significantly better at each CO. Although the Sorin
Overline showed the best diastolic performance, it showed
the highest regurgitant volumes because of its higher clo-
sure volumes. On the other hand, despite its highest trans-
valvular gradients, the Medtronic Advantage Supra
showed particularly lower regurgitant and closing vol-
umes, being significantly lower when compared with all
the other tested valves. The SJM Regent and On-X valves
showed intermediate results. For the TEL, the lowest re-
gurgitant volumes observed with the Medtronic Advantage
Supra valve led to surprising results. Despite its highest
transvalvular gradients and lowest EOA, the Medtronic
Advantage Supra valve showed the lowest TEL. On the
other hand, despite the highest regurgitant volumes, the
Sorin Overline showed an intermediate TEL and lower
than that observed with the On-X valve because of its low-
est transvalvular gradients. Native mitral valve incompe-
tence, and thus mitral prosthesis incompetence, may playrdiovascular Surgery c Volume 143, Number 3 565
FIGURE 4. Mean pressure difference, EOA, and VCVof all valves tested.
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Dan important role in left ventricle remodeling and LA pres-
sure, modifying patient clinical outcome.14 Thus, as previ-
ously reported for the aortic position,17 for a meaningful
and complete evaluation of prosthesis function it is neces-
sary to consider both systolic and diastolic phases; other-
wise, one risks a flawed analysis.
With the aim to limit these risks, we tested the prostheses
in several different conditions, increasing the SV and PR,
and thus increasing the CO, simulating hypothetic somatic
growth. Therefore, the different diastolic duration and mean
diastolic flow rate, obtained at 20 and 30 mL of SV, led to
a significant hydrodynamic modification for all the tested566 The Journal of Thoracic and Cardiovascular Surgmechanical valves. The observed transprosthetic gradients
were higher. Thus, because small flow modifications led
to significant hydrodynamic differences, it is important to
consider the results of in vitro tests for valve comparison,
and not only the use of a fixed value of in vivo measured
EOA, because in these settings the flow is an extremely vari-
able parameter.
Furthermore, according to the specific design, only the
SJM Regent, which has the pivots’ housing toward the
LA, could be placed in the supra-annular position, whereas
all the others could be placed only within the atrioventricu-
lar annulus.ery c March 2012
FIGURE 5. VLV, TRV, and TEL of all valves tested.
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DCONCLUSIONS
This hydrodynamic evaluation model allowed us to com-
pare the efficiency of currently available valve prostheses
suitable for atrioventricular replacement in children.
Among these prostheses, the Sorin Overline exhibited the
best diastolic performance, and the Medtronic Advantage
Supra showed the lowest TEL.
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